May 25, 2026 — Samsung Biologics, the world's largest contract development and manufacturing organization (CDMO) by biologics capacity, is grappling with the most severe operational disruption in its 15-year history. On May 1, 2026, approximately 2,800 union workers — representing 73% of the company's workforce — walked off the job in the first-ever full-scale strike at the Incheon-based facility.
The labor action has sent shockwaves through the global pharmaceutical supply chain. With Samsung Biologics operating four massive bioreactor facilities capable of producing over 600,000 liters of biologic drug substance annually, any disruption cascades across dozens of multinational pharmaceutical clients and their patient populations worldwide.
The financial and operational toll is staggering. Samsung Biologics has publicly estimated the impact at approximately 150 billion Korean won ($102 million), reflecting "preemptive production adjustments implemented to mitigate potential impacts across manufacturing lines." However, industry analysts suggest the true cost — including client penalties, batch failures, and reputational damage — could be significantly higher.
Production has been interrupted across 23 contract-manufactured drugs spanning critical therapeutic areas:
The nature of biologics manufacturing makes this disruption particularly damaging. Unlike small-molecule drugs that can be stockpiled, biologics require continuous cell culture processes that cannot be easily paused and restarted. Any interruption risks contamination, cell viability loss, and complete batch failure — potentially destroying products worth tens of millions of dollars per batch.
Beyond immediate production losses, the strike has raised serious regulatory concerns. The union has reported multiple "deviation events" in manufacturing that violate standard operating procedures (SOPs) during the work stoppage. For a CDMO that holds dozens of active FDA and EMA manufacturing authorizations, these deviations could trigger comprehensive regulatory inspections and remediation requirements.
A South Korean court has intervened, ordering the union to pay fines if it halts three critical manufacturing steps — specifically the continuous bioreactor processes where interruption would cause irreversible product spoilage. This legal measure, based on Good Manufacturing Practice (GMP) principles, underscores the patient safety dimension of CDMO labor disputes.
Industry experts warn that FDA scrutiny is almost certain. Any evidence of GMP non-compliance could result in warning letters, consent decrees, or suspension of manufacturing licenses — consequences that would extend far beyond Samsung Biologics to affect every pharmaceutical company relying on its facilities.
The Samsung Biologics crisis highlights a structural vulnerability in the global pharmaceutical supply chain: over-concentration of biologics manufacturing capacity in a small number of CDMOs. Samsung Biologics alone accounts for approximately 20% of global contract biologics manufacturing capacity. When this single node fails, the ripple effects are industry-wide.
This concentration risk exists against a backdrop of rapid CDMO market growth. The global CMO/CDMO market is projected to expand from USD 27.3 billion in 2026 to USD 54.2 billion by 2036, driven by pharmaceutical companies increasingly outsourcing drug development, manufacturing, and fill-finish operations. As the market grows, the consequences of supply disruptions at major CDMOs become proportionally more severe.
The BIOSECURE Act, recently enacted in the United States, adds another layer of complexity. The legislation mandates immediate re-evaluation and diversification of pharmaceutical supply chains away from designated "biotechnology companies of concern," creating additional pressure on pharmaceutical companies to reassess their CDMO partnerships.
The crisis has created a potential market redistribution opportunity. Reports from industry media indicate that Chinese and Japanese CDMO operators — including WuXi Biologics, Samsung's primary competitor, and Japanese firms — are actively positioning to capture contracts from pharmaceutical companies seeking to diversify their manufacturing base.
For B2B pharmaceutical suppliers, this shift has immediate implications. CDMO clients seeking alternative capacity will need rapid access to:
The Samsung Biologics strike offers several strategic lessons for pharmaceutical companies and their supply chain partners:
Diversification is no longer optional. Companies relying on a single CDMO for critical biologics face unacceptable concentration risk. Multi-sourcing strategies — even at higher short-term cost — provide essential supply chain resilience.
Labor relations matter in outsourcing decisions. CDMO selection criteria must extend beyond capacity, cost, and technical capability to include labor stability, union dynamics, and geopolitical risk assessment.
Contingency planning requires realism. The assumption that biologics manufacturing can be quickly transferred to alternative sites is fundamentally flawed. Biologics process transfer typically requires 12-24 months, including analytical comparability studies, regulatory submissions, and facility validation.
As tripartite talks between Samsung Biologics management, the union, and government mediators resume, the pharmaceutical industry watches closely. The resolution of this dispute will not only determine the fate of 23 disrupted drug products but may reshape how the industry evaluates CDMO risk, negotiates outsourcing contracts, and designs supply chain architectures for the biologics era.
For API and raw material suppliers, the near-term opportunity lies in supporting pharmaceutical companies as they accelerate CDMO diversification initiatives. Companies with validated supply relationships across multiple CDMO sites — and the flexibility to scale rapidly in response to shifting manufacturing patterns — are best positioned to benefit from this industry inflection point.
